2. Журтова И.Б., Эльгарова Л.В., Губачикова А.М. Иммунноопосредованные нежелательные эндокринные явления при лечении ингибиторами контрольных точек иммунного ответа: клинический опыт ниволумаб-индуцированного тиреоидита. Фарматека. 2022;7:90–4. хZhurtova I.B., Elgarova L.V., Gubachikova A.M. Immune-mediated endocrine adverse events during treatment with immune checkpoint inhibitors: a clinical case of nivolumab-induced thyroiditis Farmateka. 2022;7:90–4. (In Russ.)]. Doi: 10.18565/pharmateca.2022.7.90-94.

3. Martins F., Sofiya L., Sykiotis G.P., et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews: Clin Oncol. 2019;16:563–80. Doi: 10.1038/s41571-019-0218-0.

4. Brahmer J.R., Lacchetti C., Schneider B.J., et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. JClin. Oncol. 2018;36:1714–68. Doi: 10.1200/ JCO.2017.77.6385.

5. Castinetti F., Albarel F., Archambeaud F., et al. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocrin Relat Cancer 2019;26:G1–18. Doi: 10.1530/ERC-18- 0320.

6. Paschou S.A., Stefanaki K., Psaltopoulou T., et al. How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open. 2021;6:100011. Doi: 10.1016/j.esmoop.2020.100011.

7. Wright J.J., Powers A.C., Johnson D.B. Endocrine toxicities of immune checkpoint inhibitors. NatRev. Endocrinol. 2021;17:389–99. Doi: 10.1038/s41574-021-00484-3.

8. Di Dalmazi G., Ippolito S., Lupi I., Caturegli P. Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. Exp Rev Endocrinol Metab. 2019;14:381–98. Doi: 10.1 080/17446651.2019.1701434.

9. Bai X., Chen X., Wu X., et al. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study. J Endocrinol Invest. 2020;43:1473–83. Doi: 10.1007/s40618-020-01226-4.

10. Albarel F., Gaudy C., Castinetti F., et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172:195–204. Doi: 10.1530/EJE-14-0845.

11. Min L., Hodi F.S., Giobbie-Hurder A., et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res. 2015;21:749–55. Doi: 10.1158/1078-0432.CCR-14-2353.

12. Langlois F., Varlamov E.V., Fleseriu M. Hypophysitis, the growing spectrum of a rare pituitary disease. JClin. Endocrinol Metab. 2022;107:10–28. Doi: 10.1210/clinem/dgab672.

13. Tan M.H., Iyengar R., Mizokami-Stout K., et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diab Endocrinol. 2019;5:1. Doi: 10.1186/s40842-018-0073-4.

14. Faje A.T., Lawrence D., Flaherty K., et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124:3706–14. Doi: 10.1002/cncr.31629.

15. Stelmachowska-Banas M., Czajka-Oraniec I.Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocrin Connect. 2020;9:R207–28. Doi: 10.1530/EC-20-0342.

16. Iyer P.C., Cabanillas M.E., Waguespack S.G., et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018;28:1243–51. Doi: 10.1089/thy.2018.0116.

17. Stott D.J., Rodondi N., Kearney P.M., et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376:2534–44. https://doi. org/10.1056/NEJMoa1603825

18. de Filette J., Andreescu C.E., Cools F., et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019;51:145–56. Doi: 10.1055/a-0843-3366.

19. Wright J.J., Salem J.E., Johnson D.B., et al. Increased reporting of immune checkpoint inhibitor-associated diabetes. Diab Care. 2018;41:e150–1. Doi: 10.2337/dc18-1465.

20. Goldenberg R.M., Berard L.D., Cheng A.Y.Y., et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38:2654.e1–64. Doi: 10.1016/j.clinthera.2016.11.002.

21. Tran T.T.T., Pease A., Wood A..J., et al. Review of evidence for adult diabetic ketoacidosis management protocols. Front Endocrinol. 2017;8:106. Doi: /10.3389/fendo.2017.00106.

22. Cardona Z., Sosman J.A., Chandra S., Huang W.Endocrine side effects of immune checkpoint inhibitors. Front Endocrinol (Lausanne). 2023;14:1157805. Doi: 10.3389/fendo.2023.1157805.

23. Trevisani V., Iughetti L., Lucaccioni L., Predieri B.Endocrine immune-related adverse effects of immune-checkpoint inhibitors. Exp Rev Endocrinol Metab. 2023;18(5):441–51. Doi: 10.1080/17446651.2023.2256841.